The Side Effect
No One Warned You About:
Nail Changes During Chemotherapy
Nail toxicity affects 35–44% of taxane chemotherapy patients — and up to 89% in some regimens — yet most are never told to expect it. Here's what the peer-reviewed research shows, and what you can do about it.
- Nail toxicity affects 34.9–43.7% of taxane chemotherapy patients [1], rising to as high as 89% in some regimens [2]
- Many patients are not informed nail changes can occur before treatment begins [1,3]
- Simple daily habits and early care team conversations can meaningfully reduce severity [1]
- Peer-reviewed clinical trials support targeted topical approaches for prevention and management [6,9]
If you're going through chemotherapy, chances are you were warned to expect hair loss. But there's another side effect that catches patients completely off guard — and it happens far more often than most people realize.
Nail toxicity. Changes to your fingernails and toenails that range from cosmetic to genuinely painful, affecting your ability to button a shirt, type on a keyboard, or sleep comfortably through the night.
The research is unambiguous: nail changes occur in 34.9%[1] of patients receiving docetaxel and 43.7%[1] of those receiving paclitaxel — among the most commonly prescribed chemotherapy drugs for breast cancer. In some regimens, that figure climbs as high as 89%.[2] Yet studies consistently find that nail toxicity is one of the most under-reported and under-discussed side effects in cancer care.[1,3]
This article covers what nail toxicity is, why it happens, what to watch for, and what you can do about it — with citations from published clinical research throughout.
Why Does Chemotherapy Affect Your Nails?
Your nails grow from an area called the nail matrix — a zone of rapidly dividing cells.[4] Chemotherapy targets fast-growing cells throughout the body. While effective against cancer cells, it also disrupts healthy rapidly-dividing cells, including those in your nail matrix.
Different types of cancer treatment affect nails differently:
- Taxane chemotherapy (paclitaxel, docetaxel): disrupts nail growth and structure, causing discoloration, ridging, and separation[1,4]
- Targeted therapies: can inflame skin and nail cells, causing paronychia (nail fold infection)[4]
- Immunotherapy: may trigger immune-related nail changes[4]
- Hormonal therapy: can reduce hydration and weaken nails over time[4]
Effects typically develop gradually across treatment cycles, increasing with cumulative dose, and may persist for months after chemotherapy ends.[4,5]
What Does Nail Toxicity Look Like?
Nail changes vary widely between patients.[4] Common signs include:
- Brittle, splitting, or ridged nails (Beau's lines)
- Dark or white lines across the nail — discoloration, Mee's lines
- Nail lifting or separation from the nail bed — called onycholysis
- Inflammation, redness, or infection around the nail — called paronychia
- Subungual hematoma (bleeding under the nail)
- Increased sensitivity or pain in the nail bed
In more severe cases, partial or complete nail loss can occur.[4] Recognizing these changes early is important so supportive care can begin as soon as possible.
It's Not Just Cosmetic — The Real Impact
Nail toxicity is almost always framed as a cosmetic concern, but patients consistently report that it goes much deeper. Adverse effects of taxane chemotherapy may include physical pain, functional impairment, and a psychological impact on body image and well-being.[1]
Patients describe difficulty with everyday tasks including buttoning clothing, typing or using a phone, holding objects, walking or maintaining balance, and sleeping due to pain or sensitivity.[1,4] Because nails are visible, these changes can serve as a constant daily reminder of treatment — contributing to lower mood, social withdrawal, and changes in self-image.[4]
"I expected hair loss. I didn't expect nail damage — and it was worse."
What You Can Do: Daily Nail Care During Treatment
Keep Nails Protected
- Keep nails short and gently filed — long nails are more prone to catching and lifting[1]
- Moisturize nails and cuticles daily, especially after washing hands[1]
- Wear gloves for cleaning, gardening, and household tasks[1]
- Avoid tight footwear that puts pressure on toenails[1]
What to Avoid
- Acrylic or gel nails — can trap moisture, harbor bacteria, and mask warning signs[1]
- Cutting cuticles — increases infection risk, especially during neutropenic periods[1]
- Harsh chemicals or alcohol-based products applied directly to the nail[1]
Evidence-Based Treatment Options
Cryotherapy (Cold Gloves or Mittens)
Wearing cold gloves during chemotherapy infusion may reduce nail toxicity by restricting blood flow to the fingertips, limiting drug exposure.[7,8] A systematic review found that cryotherapy gloves and socks may be associated with reduced nail and skin changes, while calling for larger standardized clinical trials.[2]
Medical Management
If inflammation or infection develops, your oncologist may prescribe topical steroids, antibiotics, or antifungal treatments.[4] Pain management options are available — you should not feel you need to simply endure nail-related pain.
Topical Nail Balms: What Does the Research Show?
Most over-the-counter nail products have limited clinical evidence specifically for chemotherapy-induced nail damage.[1] However, a peer-reviewed, double-blind randomized controlled trial — the UK Polybalm Study — evaluated a polyphenolic-rich topical nail balm in breast cancer patients undergoing taxane-based chemotherapy.[6]
Results showed significant reductions in nail damage scores, significant improvements in quality of life, and no reported balm-related adverse effects.[6] A separate prospective RCT also reported significant reductions in docetaxel-induced onycholysis using a hydrating nail solution.[9] These represent among the few high-quality clinical trials specifically focused on chemotherapy-induced nail toxicity.
Nail Toxicity Beyond Breast Cancer: A Growing Concern
Nail toxicity is not limited to taxane chemotherapy. With the approval of newer bispecific antibody therapies such as talquetamab (Talvey®), nail-related adverse events have been reported in approximately 54–60% of patients in the pivotal MonumenTAL-1 trial, with no Grade 3 or 4 events reported.[10,11] This expanding patient population makes nail toxicity education more important than ever across oncology settings.
Why Aren't Patients Being Told About This?
Many patients are less aware of nail toxicity as an adverse reaction before treatment begins.[1,3] This is a clear educational gap — and one that oncology nurses, nurse navigators, and care teams can directly address by incorporating nail health into pre-treatment patient education.
If you haven't been told what to expect with your nails during treatment, bring it up at your next appointment. You deserve to know — and you deserve support.
A Note to Patients
If you are currently experiencing nail changes during treatment, you are not alone, and your symptoms are valid. Nail toxicity is common, can be painful and disruptive, and deserves the same attention as any other treatment side effect. Early conversations with your care team lead to earlier support and better outcomes.
- Nail toxicity affects 34.9–43.7% of taxane chemo patients, rising to as high as 89% in some regimens [1,2]
- Incidence rises to 88.5% with extended docetaxel cycles [5]
- Changes range from discoloration and ridging to painful separation and nail loss [4]
- Daily protective habits can meaningfully reduce severity [1]
- Cryotherapy and targeted topical approaches have clinical support [6,7,8,9]
- Ask your oncology team about nail care before treatment begins — not after [1,3]
All statistics and clinical claims in this article are drawn from peer-reviewed, published research. References numbered in order of first appearance.
- [1]Morrison A, Marshall-McKenna R, McFadyen AK, et al. A randomised controlled trial of interventions for taxane-induced nail toxicity in women with early breast cancer. Sci Rep. 2022;12:11575. doi:10.1038/s41598-022-13327-6
- [2]Marks DH, Qureshi A, Friedman A. Evaluation of prevention interventions for taxane-induced dermatologic adverse events: a systematic review. JAMA Dermatol. 2018;154(12):1465-1472. doi:10.1001/jamadermatol.2018.3465
- [3]Capriotti K, Capriotti JA, Lessin S. The risk of nail changes with taxane chemotherapy: a systematic review of the literature and meta-analysis. Br J Dermatol. 2015;173(3):842-845. PMID 26100137
- [4]Robert C, Sibaud V, Mateus C, et al. Nail toxicities induced by systemic anticancer treatments. Lancet Oncol. 2015;16(4):e181-189. doi:10.1016/S1470-2045(14)71133-7
- [5]Winther D, et al. Nail changes due to docetaxel — a neglected side effect and nuisance for the patient. Support Care Cancer. 2007;15:1191-1197. doi:10.1007/s00520-007-0232-0
- [6]Thomas R, Williams M, Cauchi M, Berkovitz S, Smith SA. A double-blind, randomised trial of a polyphenolic-rich nail bed balm for chemotherapy-induced onycholysis: the UK Polybalm Study. Breast Cancer Res Treat. 2018;171:103-110. doi:10.1007/s10549-018-4788-9
- [7]Scotté F, Tourani J-M, Banu E, et al. Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity. J Clin Oncol. 2005;23(19):4424-4429. doi:10.1200/JCO.2005.15.651
- [8]McCarthy AL, et al. Cryotherapy for docetaxel-induced hand and nail toxicity: randomised control trial. Support Care Cancer. 2014;22:1375-1383. doi:10.1007/s00520-013-2095-x
- [9]Kim JY, et al. A prospective randomized controlled trial of hydrating nail solution for prevention of onycholysis in breast cancer patients receiving docetaxel. Breast Cancer Res Treat. 2017;164(3):617-625. doi:10.1007/s10549-017-4268-7
- [10]Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-cell–redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387(24):2232-2244. doi:10.1056/NEJMoa2204591
- [11]Janssen Biotech. Talvey (talquetamab-tgvs) — occurrence and management of nail toxicity, MonumenTAL-1 data. J&J Medical Connect, updated March 2026. jnjmedicalconnect.com
Conflict of Interest Disclosure
The author is the Polybalm USA Support Team, and MedInnoTech LLC is the exclusive U.S. distributor of a clinically validated nail care product for chemotherapy patients. This article contains no promotional content for any specific product. All clinical claims are sourced exclusively from published, peer-reviewed research or official regulatory/prescribing information.
Disclaimer
This article is intended for patient education purposes only and does not constitute medical advice. Patients should consult their oncology care team before making any changes to their treatment or supportive care plan.
